



FOR: CARDIOCOMM SOLUTIONS, INC.  
TSX VENTURE SYMBOL: EKG

February 21, 2019

**CARDIOCOMM SOLUTIONS ENGAGES US LAW FIRM TO ADDRESS LICENSING AND IP OPPORTUNITIES**

Move is Part of Growing Sales, Marketing and Strategic Partnership Activities in the United States

**TORONTO, ONTARIO - CardioComm Solutions, Inc.** (TSX VENTURE:EKG) (“**CardioComm**” or the “**Company**”), a leading global provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, confirms it has retained Whiteford, Taylor & Preston L.L.P. to assist in software licensing and intellectual property business matters on a go forward basis.

Whiteford, Taylor & Preston includes over 170 attorneys in sixteen offices located in Delaware, the District of Columbia, Kentucky, Maryland, Michigan, New York, Pennsylvania and Virginia, and is one of the mid-Atlantic’s leading law firms.

As new opportunities develop in the US, the Company will be well served with representation from a firm located in the United States with experience in identifying, protecting, expanding and leveraging the Company’s technologies and IP assets. Further, Whiteford, Taylor & Preston meets the Company’s need for guidance from a firm with expertise in working with a medical software company that does business in both hospital and large institutional environments, as well as the consumer health and wellness sectors.

To learn more about CardioComm’s products and for further updates regarding software releases and new device integrations, please visit the Company’s websites at [www.cardiocommsolutions.com](http://www.cardiocommsolutions.com) and [www.theheartcheck.com](http://www.theheartcheck.com).

**About CardioComm Solutions**

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer

1-877-977-9425 x227

[egrima@cardiocommsolutions.com](mailto:egrima@cardiocommsolutions.com)

[investor.relations@cardiocommsolutions.com](mailto:investor.relations@cardiocommsolutions.com)

**Forward-looking statements**

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.